Stocks · News reference
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for REDEMPLO (plozasiran) to treat adults with Familial Chylomicronaemia Syndrome (FCS).
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Arrowhead Pharmaceuticals announced that REDEMPLO (plozasiran) is now available on the NHS for adults in England and Wales with Familial Chylomicronaemia Syndrome (FCS).
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.